3,3-Dimethyl-4-oxo-1-cyclopentan-carbonsaeure | 34108-23-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,3-Dimethyl-4-oxo-1-cyclopentan-carbonsaeure
• 英文别名: 3,3-dimethyl-4-oxo-cyclopentanecarboxylic acid；3,3-Dimethyl-4-oxo-cyclopentancarbonsaeure；2,2-dimethyl-4-oxocyclopentanecarboxylic acid；3.3-Dimethyl-4-oxocyclopentancarbonsaeure；Cyclopentanecarboxylic acid, 3,3-dimethyl-4-oxo-；3,3-dimethyl-4-oxocyclopentane-1-carboxylic acid
• CAS: 34108-23-1
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: QJFWCUGZPADCPK-UHFFFAOYSA-N

物化性质

• 熔点：
  93 °C
• 沸点：
  285.4±33.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,3-Dimethyl-4-oxo-1-cyclopentan-carbonsaeure 在 吡啶 、 chromium(VI) oxide 、 sodium tetrahydroborate 、 硫酸 、 sodium hydride 作用下， 以 甲醇 、 乙二醇二甲醚 、 乙醚 、 丙酮 为溶剂， 反应 10.53h， 生成 (1R*,2R*,3S*)-3-Acetoxy-2-acetoxymethyl-4,4-dimethyl-1-cyclopentan-carbonsaeure-methylester
  参考文献：
  名称：

  光化学反应115. Mitteilung [1]。Zur Photochemie konjugierterγ，δ-Epoxyenone：E-Stellung中的Der Einfluss eines羟基取代基†

  摘要：

  共轭的γ，δ-环氧烯酮的光化学：ϵ位置的羟基取代基的影响

  DOI：

  10.1002/hlca.19800630813
• 作为产物：
  描述：

  2,2-二甲基-4-戊烯酸 以 苯 为溶剂， 生成 3,3-Dimethyl-4-oxo-1-cyclopentan-carbonsaeure
  参考文献：
  名称：

  Photochemical reactions of simple cyclopentenones

  摘要：

  DOI：

  10.1021/ja00750a034

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• Studies on the sesquiterpenoids of hypolepis punctata mett.—II
  作者：Yuji Hayashi、Mugio Nishizawa、Takeo Sakan

  DOI：10.1016/0040-4020(77)80074-4

  日期：1977.1

  Hypacrone (1), a new seco-illudoid, was synthesized by several steps, including a cross aldol condensation of two major moieties, a diketone (2) and a cyclopentenone derivative (11).

  Hypacrone（1），一种新的癸二酮，是通过几个步骤合成的，包括两个主要部分的交叉羟醛缩合，二酮（2）和环戊烯酮衍生物（11）。
• Topical Noncorticosteroid Immunomodulation in the Treatment of Atopic Dermatitis
  作者：Sakari Reitamo、Anita Remitz、Hannele Kyll??nen、Johanna Saarikko、H??kan Granlund

  DOI：10.2165/00128071-200203060-00002

  日期：——

  At present, the first-line drugs for treating atopic dermatitis are topical corticosteroids. They are effective when used short-term; however, long-term use of the corticosteroids is associated with suppressive effects on the connective tissue, seen as skin atrophy or resistance to therapy. Currently, two topical noncorticosteroid immunomodulators tacrolimus (FK506) and pimecrolimus (SDZ ASM 981) are under development, or already on the market in some countries for atopic dermatitis. These two compounds show structural similarity. In T lymphocytes they bind to the same cellular receptor, the FK-binding protein (FKBP) or macrophilin- 12. Tacrolimus shows a 3-fold greater affinity to FKBP compared with pimecrolimus. The tacrolimus/ pimecrolimus-FKBP complex further binds to calcineurin, an enzyme vital for the early activation of T cells. The consequence of calcineurin binding is a lack of activation of both T helper cell types 1 and 2. Further effects of these compounds have been suggested on other inflammatory cells, such as Langerhans cells and mast cells/basophils. In contrast to corticosteroids, no suppressive effects on connective tissue cells have been observed. Taken together, treatment of inflammation results in healing of the barrier function of the skin. This again results in reduced bioavailability of the drug, as compared with systemic use. Placebo-controlled studies have shown the efficacy of both tacrolimus (at 0.03 and 0.1%) and pimecrolimus (at 0.6 and 1%). The main adverse event in these studies has been a burning sensation and increased pruritus at the site of application. Typically, these adverse events are observed only during the first days of treatment. Long-term safety studies, of up to one year, have not revealed any new adverse events. So far, long-term use of topical noncorticosteroid compounds has not been associated with signs of immune deficiency. Although there is currently no evidence for clinically relevant, prolonged adverse effects, some of these, such as an increased risk of photocarcinogenesis, need to be monitored. There is evidence from tacrolimus studies that monotherapy results in better long-term results when compared with combination therapy with corticosteroids. Tacrolimus and pimecrolimus could replace topical corticosteroids as the first-line treatment of atopic dermatitis.

  in the18-19岁 18-19岁 18-19岁 18-1
• Bardhan; Banerji; Bose, Journal of the Chemical Society, 1935, p. 1128
  作者：Bardhan、Banerji、Bose

  DOI：——

  日期：——
• US4117014A
  申请人：——

  公开号：US4117014A

  公开（公告）日：1978-09-26